References
- Ala, M., 2022. Sestrin2 in cancer: a foe or a friend? Biomarker Research, 10 (1), 29.
- Andersen, J., 1998. Factors in fibroid growth. Bailliere’s Clinical Obstetrics and Gynaecology, 12 (2), 225–243.
- Batlle, E. and Clevers, H., 2017. Cancer stem cells revisited. Nature Medicine, 23 (10), 1124–1134.
- Byun, J.-K., et al., 2017. A positive feedback loop between Sestrin2 and mTORC2 ıs required for the survival of glutamine-depleted lung cancer cells. Cell Reports, 20 (3), 586–599.
- Chae, H.S., et al., 2020. Sestrin 2 expression has regulatory properties and prognostic value in lung cancer. Journal of Personalized Medicine, 10 (3), 109.
- Chen, K.-B., et al., 2016. Sestrin 2 expression is a favorable prognostic factor in patients with non-small cell lung cancer. American Journal of Translational Research, 8 (4), 1903–1909.
- Chiaffarino, F., et al., 2016. Cigarette smoking and risk of uterine myoma: systematic review and meta-analysis. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 197, 63–71.
- Chiaffarino, F., et al., 2017. Alcohol consumption and risk of uterine myoma: a systematic review and meta analysis. PLoS One, 12 (11), e0188355.
- Farquhar, C.M. and Steiner, C.A., 2002. Hysterectomy rates in the United States 1990–1997. Obstetrics and Gynecology, 99 (2), 229–234.
- Gonzalez-Mercado, V.J., Fridley, B.L. and Saligan, L.N., 2018. Sestrin family of genes and their role in cancer-related fatigue. Supportive Care in Cancer, 26 (7), 2071–2074.
- Haidurov, A. and Budanov, A.V., 2020. Sestrin family – the stem controlling healthy ageing. Mechanisms of Ageing and Development, 192, 111379.
- Laganà, A.S., et al., 2017. Epigenetic and genetic landscape of uterine leiomyomas: a current view over a common gynecological disease. Archives of Gynecology and Obstetrics, 296 (5), 855–867.
- Lee, J.H., Budanov, A.V. and Karin, M., 2013. Sestrins orchestrate cellular metabolism to attenuate aging. Cell Metabolism, 18 (6), 792–801.
- Liang, Y., et al., 2016. SESN2/sestrin 2 induction-mediated autophagy and inhibitory effect of isorhapontigenin (ISO) on human bladder cancers. Autophagy, 12 (8), 1229–1239.
- McWilliams, M.M. and Chennathukuzhi, V.M., 2017. Recent advances in uterine fibroid etiology. Seminars in Reproductive Medicine, 35 (2), 181–189.
- Parazzini, F., et al., 2003. Uterine fibroids risk and history of selected medical conditions linked with female hormones. European Journal of Epidemiology, 19 (3), 249–253.
- Rein, M.S., Barbieri, R.L. and Friedman, A.J., 1995. Progesterone: a critical role in the pathogenesis of uterine myomas. American Journal of Obstetrics and Gynecology, 172 (1 Pt 1), 14–18.
- Ro, S.-H., et al., 2016. Tumor suppressive role of sestrin2 during colitis and colon carcinogenesis. eLife, 5, e12204.
- Saeedi, V., et al., 2021. Sestrin2 and Beclin1 levels in polycystic ovary syndrome. Journal of Clinical Laboratory Analysis, 35 (9), e23957.
- Shin, J., et al., 2020. mTOR-dependent role of Sestrin2 in regulating tumor progression of human endometrial cancer. Cancers, 12 (9), 2515.
- Styer, A.K. and Rueda, B.R., 2016. The epidemiology and genetics of uterine leiomyoma. Best Practice & Research. Clinical Obstetrics & Gynaecology, 34, 3–12.
- Vitagliano, A., et al., 2018. Uterine fibroid size modifications during pregnancy and puerperium: evidence from the first systematic review of literature. Archives of Gynecology and Obstetrics, 297 (4), 823–835.
- Wei, J.-L., et al., 2017. Sestrin 2 suppresses cells proliferation through AMPK/mTORC1 pathway activation in colorectal cancer. Oncotarget, 8 (30), 49318–49328.
- Whitaker, L. and Critchley, H.O.D., 2016. Abnormal uterine bleeding. Best Practice & Research. Clinical Obstetrics & Gynaecology, 34, 54–65.
- Wise, L.A. and Laughlin-Tommaso, S.K., 2016. Epidemiology of uterine fibroids: from Menarche to Menopause. Clinical Obstetrics and Gynecology, 59 (1), 2–24.
- Wolman, I., 2014. Berek and Novak’s Gynecology 15th Edition. The Journal of Obstetrics and Gynecology of India, 64 (2), 150–151.
- Xu, X., et al., 2021. Inhibition of sestrin 1 alleviates polycystic ovary syndrome by decreasing autophagy. Aging, 13 (8), 11774–11785.
- Zhao, B., et al., 2014. Sestrin2 protein positively regulates AKT enzyme signaling and survival in human squamous cell carcinoma and melanoma cells. The Journal of Biological Chemistry, 289 (52), 35806–35814.